|
|
||||||||




*
Department of Otolaryngology, School of Medicine, Hokkaido University, Sapporo, Japan; and
Section of Pathology, Institute of Immunological Science, Hokkaido University, Sapporo, Japan
Activation of APC via CD40-CD40 ligand pathway induces
up-regulation of costimulatory molecules such as B7 and production of
IL-12. Interaction between B7 on APC and CD28 on naive T cells is
necessary for priming the T cells. On the other hand, interaction
between B7 on APC and CTLA-4 on activated T cells transduces a negative
regulatory signal to the activated T cells. In the present study, we
attempted to generate tumor-specific CTL by s.c. administration of
antigenic peptides encapsulated in multilamellar liposomes (liposomal
peptide vaccine) with anti-CD40 mAb and/or anti-CTLA-4 mAb.
Liposomal OVA257264 and anti-CD40 mAb or
anti-CTLA-4 mAb were administrated to C57BL/6 mice and the
splenocytes were cocultured with OVA257264 for 4 days.
The splenic CD8+ T cells showed a significant cytotoxicity
against EL4 cells transfected with cDNA of OVA. In addition,
administration of both anti-CD40 and anti-CTLA-4 mAb enhanced
the CTL responses. Considerable CTL responses were induced in MHC class
II deficient mice by the same procedure. This finding indicated that
CTL responses could be generated even in the absence of Th cells. When
BALB/c mice were immunized with pRL1a peptide that are tumor-associated
Ag of RL
1 leukemia cells using the same procedure, significant CTL
responses were induced and prolonged survival of the BALB/c mice was
observed following RL
1 inoculation. These results demonstrate that
anti-CD40 mAb and anti-CTLA-4 mAb function as immunomodulators
and may be applicable to specific cancer immunotherapy with antitumor
peptide vaccine.
This article has been cited by other articles:
![]() |
M.-G. de Goer de Herve, D. Durali, T.-A. Tran, G. Maigne, F. Simonetta, P. Leclerc, J.-F. Delfraissy, and Y. Taoufik Differential effect of agonistic anti-CD40 on human mature and immature dendritic cells: the Janus face of anti-CD40 Blood, October 15, 2005; 106(8): 2806 - 2814. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Madrenas, L. A. Chau, W. A. Teft, P. W. Wu, J. Jussif, M. Kasaian, B. M. Carreno, and V. Ling Conversion of CTLA-4 from Inhibitor to Activator of T Cells with a Bispecific Tandem Single-Chain Fv Ligand J. Immunol., May 15, 2004; 172(10): 5948 - 5956. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-Y. Wu, R. K. Taylor, and W. F. Wade Anti-Class II Monoclonal Antibody-Targeted Vibrio cholerae TcpA Pilin: Modulation of Serologic Response, Epitope Specificity, and Isotype Infect. Immun., December 1, 2001; 69(12): 7679 - 7686. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Hernandez, A. Ko, and L. A. Sherman CTLA-4 Blockade Enhances the CTL Responses to the p53 Self-Tumor Antigen J. Immunol., March 15, 2001; 166(6): 3908 - 3914. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Siemens, B. D. Elzey, D. M. Lubaroff, C. Bohlken, R. J. Jensen, A. K. Swanson, and T. L. Ratliff Cutting Edge: Restoration of the Ability to Generate CTL in Mice Immune to Adenovirus by Delivery of Virus in a Collagen-Based Matrix J. Immunol., January 15, 2001; 166(2): 731 - 735. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Krishnan, S. Sad, G. B. Patel, and G. D. Sprott Archaeosomes Induce Long-Term CD8+ Cytotoxic T Cell Response to Entrapped Soluble Protein by the Exogenous Cytosolic Pathway, in the Absence of CD4+ T Cell Help J. Immunol., November 1, 2000; 165(9): 5177 - 5185. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Namba, K. Ogasawara, N. Kitaichi, T. Morohashi, Y. Sasamoto, S. Kotake, H. Matsuda, K. Iwabuchi, C. Iwabuchi, S. Ohno, et al. Amelioration of Experimental Autoimmune Uveoretinitis by Pretreatment with a Pathogenic Peptide in Liposome and Anti-CD40 Ligand Monoclonal Antibody J. Immunol., September 15, 2000; 165(6): 2962 - 2969. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |